[1]范 雪a,秦文沛b,唐钰姣a,等.代谢综合征患者血清25 (OH)D和GDF 15水平表达与并发甲状腺结节发生恶性风险的相关性研究[J].现代检验医学杂志,2024,39(06):147-151+194.[doi:10.3969/j.issn.1671-7414.2024.06.025]
　FAN Xuea,QIN Wenpeib,TANG Yujiaoa,et al.Study on the Correlation between the Expression of Serum 25(OH)D and GDF15 Levels and the Risk of Malignancy in Combined Thyroid Nodules in Patients with Metabolic Syndrome[J].Journal of Modern Laboratory Medicine,2024,39(06):147-151+194.[doi:10.3969/j.issn.1671-7414.2024.06.025]
点击复制

代谢综合征患者血清25 (OH)D和GDF 15水平表达与并发甲状腺结节发生恶性风险的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年06期
页码:
147-151+194
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
Study on the Correlation between the Expression of Serum 25(OH)D and GDF15 Levels and the Risk of Malignancy in Combined Thyroid Nodules in Patients with Metabolic Syndrome
文章编号:
1671-7414（2024）06-147-06
作者:
范 雪a; 秦文沛b; 唐钰姣a; 杨晓萍a
（新疆医科大学第一附属医院 a. 健康管理中心健康体检部；b. 医学检验中心，乌鲁木齐 830063）
Author(s):
FAN Xuea;  QIN Wenpeib;  TANG Yujiaoa;  YANG Xiaopinga
（a. Department of Physical Examination, Health Management Cente；b. Center of Laboratory Medicine，the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China）
关键词:
25 羟基维生素D; 生长分化因子15; 代谢综合征并发甲状腺结节
分类号:
R589；R581.9；R446.11
DOI:
10.3969/j.issn.1671-7414.2024.06.025
文献标志码:
A
摘要:
目的 探讨代谢综合征(metabolic syndrome，MS) 患者血清25 羟基维生素D [25(OH)D]，生长分化因子15（growth differentiation factor 15，GDF-15）水平表达与并发甲状腺结节（thyroid nodules，TN）发生恶性风险的相关性。方法 选取2019 年8 月～ 2023 年8 月在新疆医科大学第一附属医院就诊的185 例MS 患者作为研究对象，按照甲状腺超声检查结果将其分为MS 组（n=73）和MS+TN 组（n=112），并根据甲状腺结节恶性分级将MS+TN 组患者分为良性组（n=89）及恶性组（n=23）；另选取同期体检的68 例体检健康者作为对照组。采用酶联免疫吸附法（ELISA）测定各组血清25(OH)D 和GDF-15 水平；Pearson 分析血清25(OH)D 和GDF-15 水平与MS 并发TN 患者临床指标之间的相关性；多因素Logistic 回归分析MS 并发TN 患者发生恶性TN 的影响因素；绘制受试者工作特征（ROC）曲线评估血清25(OH)D和GDF-15水平对MS并发恶性TN的诊断价值。结果 对照组、MS组、MS+TN组血清25(OH)D（30.41±6.73ng/ml，27.23±6.15 ng/ml，24.67±4.38 ng/ml）和GDF-15（167.99±22.56 ng/L，239.75±25.92 ng/L，286.63±26.04 ng/L）水平比较，差异具有统计学意义（F=22.219，472.113，均P ＜ 0.05）；且与良性组相比，恶性组患者血清25(OH)D（26.28±4.53 ng/ml vs 18.44±3.79 ng/ml）水平明显降低，GDF-15（276.93±24.53 ng/L vs 324.17±31.89 ng/L）水平明显升高，差异具有统计学意义（t=7.631，7.718，均P ＜ 0.05）。恶性组患者BMI，年龄、FPG，TG，TSH 和TGAb 水平明显高于良性组，差异具有统计学意义（t=2.868，3.523，3.542，3.603，4.581，5.516，均P ＜ 0.05）. Pearson 相关分析，MS并发TN 患者血清25(OH)D 水平与FPG，TSH，TG 和TGAb 水平均呈负相关（r=-0.302，-0.482，-0.524，-0.546，均P ＜ 0.05），GDF-15 水平与TG，TSH，TGAb 和FPG 水平均呈正相关（r=0.467，0.541，0.578，0.623，均P ＜ 0.001）。多因素Logistic 回归分析，GDF-15（OR=1.673，95%CI：1.146 ～ 2.442）为MS 患者恶性TN 发生的危险因素（P ＜ 0.05），25(OH)D（OR=0.744，95%CI：0.604 ～ 0.916）为恶性TN 发生的保护因素（P ＜ 0.05）；血清25(OH)D 和GDF-15 水平单独及联合诊断MS 并发恶性TN 的AUC 分别为0.813，0.799，0.930，联合诊断优于单独诊断（Z =2.088，2.021，P=0.037，0.043）。结论 MS 并发TN 患者血清25(OH)D，GDF-15 水平与其结节性质明显相关，血清25(OH)D 水平降低和GDF-15 水平升高是MS 患者发生恶性TN 的危险因素。
Abstract:
Objective To investigate the correlation between the expression of serum 25hydroxyvitamin D [25(OH)D] and growth differentiation factor 15（GDF-15） levels and the risk of malignancy in patients with metabolic syndrome (MS) and the development of combined thyroid nodules (TN). Methods From August 2019 to August 2023, 185 MS patients who visited the First Affiliated Hospital of Xinjiang Medical University were regarded as the study subjects, according to the results of thyroid ultrasound examination, they were separated into MS group (n=73) and MS+TN group (n=112). According to the malignant grading of thyroid nodules, MS+TN patients were separated into benign group (n=89) and malignant group (n=23). Another 68 healthy individuals who underwent physical examinations were regarded as control group. Enzyme-linked immunosorbent assay (ELISA) was applied to determine the levels of serum 25(OH)D and GDF-15 in each group. Pearson was applied to analyze the correlation between serum 25(OH)D and GDF-15 levels and clinical indicators in MS in TN patients. Multivariate Logistic regression was applied to analyze the influencing factors of malignant TN in patients with MS combined with TN. Receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic value of serum 25(OH)D and GDF-15 levels in MS with malignant TN. Results Comparison of serum 25(OH)D（30.41±6.73 ng/ml，27.23±6.15 ng/ml，24.67±4.38 ng/ ml） and GDF-15 （167.99±22.56 ng/L，239.75±25.92 ng/L，286.63±26.04 ng/L）levels in control, MS and MS+TN groups, the differences were statistically significant (F=22.219, 472.113, all P<0.05). Compared with the benign group, the serum 25(OH)D（26.28±4.53 ng/ml vs 18.44±3.79 ng/ml） level in the malignant group was obviously reduced, while the GDF-15 （276.93±24.53 ng/L vs 324.17±31.89 ng/L）level was obviously increased, the differences were statistically significan（t t=7.631， 7.718，all P ＜ 0.05）. The BMI, age, FPG, TG, TSH and TGAb levels of patients in the malignant group were obviously higher than those in the benign group，the difference were statistically significant（t=2.868，3.523，3.542，3.603，4.581，5.516， all P ＜ 0.05）. Pearson correlation analysis, and the serum 25(OH)D level in MS patients with TN was negatively correlated with FPG, TSH, TG and TGAb levels (r= -0.302，-0.482，-0.524，-0.546，all P<0.001), while GDF-15 level was positively correlated with TG, TSH, TGAb and FPG levels (r=0.467，0.541，0.578，0.623, all P<0.05). Multivariate logistic regression analysis, GDF-15（OR=1.673，95%CI：1.146 ～ 2.442） was a risk factor for the occurrence of malignant TN in MS patients (P<0.05), and 25(OH)D（OR=0.744，95%CI：0.604 ～ 0.916）was a protective factor for the occurrence of malignant TN, the AUC values of serum 25(OH)D and GDF-15 levels in the diagnosis of MS combined with malignant TN were 0.813, 0.799 and 0.930, respectively, and the combination was superior to the single diagnosis （Z =2.088, 2.021, P=0.037，0.043）. Conclusion The levels of serum 25(OH)D and GDF-15 in patients with MS combined with TN are obviously correlated with nodular nature. The decrease in serum 25(OH)D level and the increase in GDF-15 level are risk factors for malignant TN in MS patients.

参考文献/References:

[1] CHO Y, LEE S Y. Useful biomarkers of metabolic syndrome[J]. International Journal of Environmental Research and Public Health, 2022, 19(22): 15003.
[2] 宋晓龙, 宋宇, 魏龙, 等. 血清TK1,TSH,TG,TGAb检测联合TI-RADS 分类在甲状腺乳头状癌早期筛查中的应用价值[J]. 现代检验医学杂志, 2022, 37(4):38-42. SONG Xiaolong, SONG Yu, WEI Long, et al. Clinical value of serum TK1, TSH, TG and TGAb detection combined with TI-RADS classification in papillary thyroid carcinoma[J]. Journal of Modern Laboratory Medicine, 2022, 37(4): 38-42.
[3] 索艳, 王肃. 甲状腺疾病与代谢综合征关系的研究[J]. 医学信息, 2022, 35(4): 53-56. SUO Yan, WANG Su. Study on the relationship between thyroid diseases and metabolic syndrome[J]. Medical Information, 2022, 35(4): 53-56.
[4] 何庆远, 闫慧明. 代谢综合征与分化型甲状腺癌的发生及严重程度的相关性[J]. 现代肿瘤医学, 2023,31(13): 2443-2447. HE Qingyuan, YAN Huiming. Corralation between metabolic symdrome and the occurrence and severity of differentiated thyroid carcinoma[J]. Journal of Modern Oncology, 2023, 31(13): 2443-2447.
[5] 延华, 李敏. NAFLD 患者血清25(OH)D3,Vaspin 和AIP 水平及其与疾病严重程度的相关性研究[J]. 现代检验医学杂志, 2023, 38(6): 125-130. YAN Hua, LI Min. Serum vitamin D,Vaspin,AIP levels and their correlation with disease severity in patients with NAFLD[J]. Journal of Modern Laboratory Medicine, 2023, 38(6): 125-130.
[6] SHAN Xiaoyun, ZHAO Xiayu, LI Siran, et al. Association of serum 25(OH)D with metabolic syndrome in Chinese women of childbearing age[J]. Nutrients, 2022, 14(11): 2301.
[7] ABDELLATEIF M S, SHAARAWY S, ELESAWY Y F, et al. The role of vitamin D, platelet-derived growth factor and insulin-like growth factor 1 in the progression of thyroid diseases[J]. Asian Pacific Journal of Cancer Prevention, 2020, 21(7): 2083-2089.
[8] 李小琴, 余广兰. 急性缺血性脑卒中患者血清Cav-1和GDF-15 表达水平及对预后的评估价值研究[J].现代检验医学杂志, 2022, 37(4): 118-122, 127. LI Xiaoqin, YU Guanglan. Expression levels of serum Cav-1 and GDF-15 and their prognostic value in patients with acute ischemic stroke[J]. Journal of Modern Laboratory Medicine, 2022, 37(4): 118-122,127.
[9] WISCHHUSEN J, MELERO I, FRIDMAN W H. Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint[J]. Frontiers in Immunology, 2020, 11: 951.
[10] 中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J]. 中华糖尿病杂志, 2004, 12(3): 156-161. Collaborative Group on Metabolic Syndrome Research,Diabetes Branch, Chinese Medical Association. Recommendations of the Chinese medical association diabetes branch on metabolic syndrome[J]. Chinese Journal of Diabetes, 2004, 12(3): 156-161.
[11] TESSLER F N, MIDDLETON W D, GRANT E G, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee[J]. Journal of the American College of Radiology, 2017, 14(5): 587-595.
[12] ZHANG Chenyu, GAO Xiaotong, HAN Yutong, et al. Correlation between thyroid nodules and metabolic syndrome: a systematic review and meta-analysis[J]. Frontiers in Endocrinology, 2021, 12: 730279.
[13] LI Yongze, TENG Di, BA Jianming, et al. Efficacy and safety of Long-Term Universal salt iodization on thyroid disorders: epidemiological evidence from 31 provinces of mainland China[J]. Thyroid, 2020, 30(4): 568-579.
[14] 施权, 邱国春. US-FNA 联合CK-19, TPO 检测对C-TIRADS 4A/4B 分类甲状腺结节的诊断价值[J].中国现代医学杂志, 2023, 33(22): 76-81. SHI Quan, QIU Guochun. Diagnostic value of US-FNA combined with CK-19 and TPO for C-TIRADS 4A/4B thyroid nodules[J]. China Journal of Modern Medicine,2023, 33(22): 76-81.
[15] 桑贵蕊, 杭宇, 叶勇健, 等. 血清25 羟维生素D 在2 型糖尿病合并代谢综合征中的临床意义[J]. 糖尿病新世界, 2023, 26(11): 20-23. SANG Guirui, HANG Yu, YE Yongjian, et al. Clinical significance of serum 25 hydroxyvitamin D in the combined metabolic syndrome of type 2 diabetes mellitus[J]. Diabetes New World, 2023, 26(11): 20-23.
[16] BABI? LEKO M, JURE?KO I, ROZI? I, et al. Vitamin D and the thyroid: a critical review of the current evidence[J]. International Journal of Molecular Sciences, 2023, 24(4): 3586.
[17] LI Fang, SUN Wei, LIU Lihua, et al. The application value of CDFI and SMI combined with serological markers in distinguishing benign and malignant thyroid nodules[J]. Clinical and Translational Oncology, 2022,24(11): 2200-2209.
[18] BAEK S J, ELING T. Growth differentiation factor 15 (GDF15): a survival protein with therapeutic potential in metabolic diseases[J]. Pharmacology Therapeutics,2019, 198: 46-58.
[19] 王丽萍, 刘云, 柴巧英, 等. T2DM 患者GDF-15,NRG4 水平对并发甲状腺功能亢进的预测价值[J].中南医学科学杂志, 2023, 51(4): 541-544. WANG Liping, LIU Yun, CHAI Qiaoying, et al. Predictive value of GDF-15 and NRG4 levels in patients with T2DM complicated by hyperthyroidism[J]. Medical Science Journal of Central South China, 2023,51(4): 541-544.
[20] CARBALLO-CASLA A, GARC?A-ESQUINAS E,BU?O-SOTO A, et al. Metabolic syndrome and growth differentiation factor 15 in older adults[J]. Geroscience,2022, 44(2): 867-880.
[21] KANG Y E, KIM J M, LIM M A, et al. Growth differentiation factor 15 is a cancer cell-induced mitokine that primes thyroid cancer cells for invasiveness[J]. Thyroid, 2021, 31(5): 772-786.
[22] PERUMAL P V, SIDDARAJU N, SAXENA S K, et al. Utility of the growth differentiation factor-15 in the differential diagnosis of follicular-patterned lesions of the thyroid on cytopathologic and histopathologic samples[J]. Cureus, 2023, 15(9): e46206.

相似文献/References:

[1]李玄丹,李材忠,唐永婕,等.老年ARDS 患者血清FGF-21，GDF-15 及PTX-3 表达水平及其与病情评估和预后的相关性研究[J].现代检验医学杂志,2022,37(04):188.[doi:10.3969/j.issn.1671-7414.2022.04.037]
　LI Xuan-dan,LI Cai-zhong,TANG Yong-jie,et al.Expression Levels of Serum FGF-21, GDF-15 and PTX-3 in Elderly Patients with ARDS and Their Correlation with Disease Evaluation and Prognosis[J].Journal of Modern Laboratory Medicine,2022,37(06):188.[doi:10.3969/j.issn.1671-7414.2022.04.037]
[2]朱 磊a,徐妍妍a,盛利平a,等.手足口病患儿血清FGF-21 与GDF-15 水平检测的临床诊疗应用研究[J].现代检验医学杂志,2023,38(05):180.[doi:10.3969/j.issn.1671-7414.2023.05.034]
　ZHU Leia,XU Yanyana,SHENG Lipinga,et al.Research on the Application of Serum FGF-21 and GDF-15 in Clinical Diagnosis and Treatment of Children with Hand, Foot and Mouth Disease[J].Journal of Modern Laboratory Medicine,2023,38(06):180.[doi:10.3969/j.issn.1671-7414.2023.05.034]

备注/Memo

备注/Memo:
基金项目：新疆医科大学第一附属医院2022 年度青年科研启航专项基金项目（编号：2022YFY-QKQN-23）。
作者简介：范雪（1988-），女，医学硕士，主治医师，研究方向：腹部及浅表器官超声诊断，E-mail: vgtwvw@163.com。
更新日期/Last Update: 2024-11-15